<?xml version="1.0" encoding="UTF-8"?>
<ref id="B43-pharmaceuticals-13-00096">
 <label>43.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hoffman</surname>
    <given-names>K.B.</given-names>
   </name>
   <name>
    <surname>Demakas</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Erdman</surname>
    <given-names>C.B.</given-names>
   </name>
   <name>
    <surname>Dimbil</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Doraiswamy</surname>
    <given-names>P.M.</given-names>
   </name>
  </person-group>
  <article-title>Neuropsychiatric adverse effects of oseltamivir in the FDA adverse event reporting system, 1999â€“2012</article-title>
  <source>BMJ</source>
  <year>2013</year>
  <volume>347</volume>
  <fpage>f4656</fpage>
  <pub-id pub-id-type="doi">10.1136/bmj.f4656</pub-id>
  <?supplied-pmid 23881998?>
  <pub-id pub-id-type="pmid">23881998</pub-id>
 </element-citation>
</ref>
